Pancreatic cancer is notoriously difficult to catch in its early stages and treat effectively. (Image credit: Science Photo Library - STEVE GSCHMEISSNER via Getty Images) An experimental treatment has doubled one-year survival rates for pancreatic cancer, one of the deadliest types of cancer , a new study reports. The drug, called elraglusib, targets the protective web that pancreatic tumors build around themselves, thus helping immune molecules and chemotherapy better penetrate the tumors. The results of the trial showing elraglusib's safety and efficacy were published April 14 in the journal Nature Medicine . A rare win in pancreatic cancer treatment Pancreatic cancer has one of the poorest prognoses of all cancers, with patients who are newly diagnosed having only a 13% chance of surviving five years with the disease.…